Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC

NCT01496742 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01496742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01496742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
November 30, 2015
Enrollment
259 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer